Recombinant and Autologous Platelet-Derived Growth Factors (PRP) for Wound Healing and Other Non-Orthopedic Conditions
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage and medical necessity determinations for autologous platelet-rich plasma (PRP) used to treat wounds and other non-orthopedic conditions for Blue Cross Blue Shield - Rhode Island members, distinguishing Medicare Advantage and commercial product stances.
No material clinical or coverage changes in this revision.
Coverage Criteria
Medicare Advantage - Covered Indication
Covered when ALL of the following are met:
CMS specified coverage is for a duration of 20 weeks; extension beyond 20 weeks is determined by local Medicare Administrative Contractors (MACs).
Commercial - Not Medically Necessary
Not medically necessary when ALL of the following are met:
When billed for commercial products, HCPCS code G0465 is not considered a covered service for these indications per the policy coding guidance.
This policy distinguishes between Medicare Advantage and commercial products. For Medicare Advantage, autologous platelet-rich plasma (PRP) is covered when used to treat chronic non‑healing diabetic wounds and is filed with a covered diagnosis; coverage is limited to devices with appropriate FDA‑cleared indications for management of exuding cutaneous wounds and follows CMS direction (including a specified coverage duration of 20 weeks). For commercial products, use of autologous PRP for acute or chronic wounds — including surgical wounds and nonhealing ulcers — is considered not medically necessary due to insufficient evidence of benefit.
Coverage, exclusions, and specific benefit determinations are governed by the member’s subscriber agreement or employer agreement. Those documents supersede the medical policy for purposes of payment and eligibility; providers should contact the provider call center for member‑specific benefits and eligibility information.
For commercial products, autologous PRP is considered not medically necessary for the treatment of any acute or chronic wounds, including surgical wounds and nonhealing ulcers. In addition, HCPCS code G0460 (autologous PRP for non‑diabetic chronic wounds/ulcers) is specifically listed as not covered/not medically necessary.
Services determined to be not medically necessary (or services that are medically necessary but are non‑covered benefits under the member’s plan) are not covered. Providers may not bill the member for such services unless the member was informed in advance and agreed in writing to be responsible for the cost.
Coding
| G0465 | Autologous platelet rich plasma (PRP) for diabetic chronic wounds/ulcers, using an FDA-cleared device (includes administration, dressings, phlebotomy, centrifugation, and all other preparatory procedures, per treatment) |
| G0460 | Autologous platelet rich plasma for non-diabetic chronic wounds/ulcers, including phlebotomy, centrifugation, and all other preparatory procedures, administration and dressings, per treatment |
Provider Actions & Billing Guidance
Prior Authorization
Not applicable
Check Eligibility / Benefits
Check member eligibility and benefits with the payer or refer to the member's Evidence of Coverage / Subscriber Agreement for group-specific coverage and benefit variations.
Benefit Verification
Benefits may vary among groups. Refer to the member's benefit booklet, Evidence of Coverage, or Subscriber Agreement for services that may be not medically necessary.
Coding and Coverage Guidance
For Medicare Advantage Plans the following HCPCS is covered when filed with a covered diagnosis; for Commercial Products the service is considered not medically necessary for wounds and may be denied.
- G0465 — Autologous platelet rich plasma (PRP) for diabetic chronic wounds/ulcers, using an FDA‑cleared device (includes administration, dressings, phlebotomy, centrifugation, and all preparatory procedures) — covered for Medicare Advantage when billed with a covered diagnosis
- G0460 — Autologous platelet rich plasma for non‑diabetic chronic wounds/ulcers — not covered for Medicare Advantage and considered not medically necessary for Commercial Products
Commercial Product Denial Risk
Use caution: platelet-rich plasma (autologous blood-derived preparations) is considered not medically necessary for treatment of acute or chronic wounds (including surgical wounds and nonhealing ulcers) for Commercial Products; there is a risk of claim denial for these indications.
Member Charge / Denial Risk
If services are determined to be not medically necessary or are non‑covered benefits, you may not charge the member for those services unless the member was informed in advance and provided written agreement to self-pay. Contact the provider call center for member‑specific benefit and eligibility details.
Background
Platelet‑rich plasma (PRP) is an autologous concentrate of platelets prepared from a patient’s own blood by centrifugation. The platelet concentrate is suspended in plasma and can be activated (for example, with thrombin and calcium chloride) to release growth factors such as platelet‑derived growth factor (PDGF), transforming growth factor (TGF), and vascular endothelial growth factor (VEGF). Activated PRP forms a platelet gel that may be applied topically to wounds with the aim of promoting wound healing, and has been evaluated in randomized trials and meta‑analyses for chronic wounds, particularly diabetic lower‑extremity ulcers; however, the evidence base has limitations in study quality, precision, and generalizability.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.